Literature DB >> 24270518

Vulvar cancer surgery.

Glauco Baiocchi1, Rafael M Rocha.   

Abstract

PURPOSE OF REVIEW: Surgical treatment of vulvar cancer has been shifted from ultraradical procedures associated with huge morbidity to less extensive surgery with better psychosexual result and less morbidity, without compromising survival. The authors review and discuss the recent literature regarding the surgical management of vulvar squamous cell carcinoma. RECENT
FINDINGS: Surgery remains the cornerstone in the treatment of vulvar cancer. Radical vulvectomy with inguinofemoral lymphadenectomy has been replaced by radical local excision with sentinel node procedure for early disease. However, the role and distance of pathological margins are still on debate. Recent results from a large prospective trial corroborate the safety of sentinel node biopsy for early disease, even after primary tumor resection. An experienced team should perform sentinel node procedure using combined technique (blue dye and lymphoscintigraphy) and ultrastaging pathology. Moreover, midline tumors still need lymph node biopsy from both groins.
SUMMARY: Primary vulvar cancer may be safely treated with radical/wide local resection. In case of other suspicious lesion or multifocal disease, radical vulvectomy is performed. Patients with unifocal disease, tumor size less than 4 cm, and clinically negative groins are candidates to sentinel node procedure. In the case of clinically positive node or sentinel node metastasis, a systematic inguinofemoral lymphadenectomy should be performed.

Entities:  

Mesh:

Year:  2014        PMID: 24270518     DOI: 10.1097/GCO.0000000000000033

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  8 in total

1.  Abdominoperineal Excisions in the Treatment Regimen for Advanced and Recurrent Vulvar Cancers-Analysis of a Single-Centre Experience.

Authors:  Sabine Hannes; Johanna M Nijboer; Alexander Reinisch; Wolf O Bechstein; Nils Habbe
Journal:  Indian J Surg       Date:  2015-04-24       Impact factor: 0.656

2.  Sentinel lymph node procedure in patients with recurrent vulvar squamous cell carcinoma: a proposed protocol for a multicentre observational study.

Authors:  Helena C van Doorn; Maaike H M Oonk; Guus Fons; Katja N Gaarenstroom; Joanne de Hullu; Joost van Rosmalen; Heleen J van Beekhuizen
Journal:  BMC Cancer       Date:  2022-04-23       Impact factor: 4.638

Review 3.  The giant steps in surgical downsizing toward a personalized treatment of vulvar cancer.

Authors:  Andrea Giannini; Ottavia D'Oria; Benito Chiofalo; Valentina Bruno; Ermelinda Baiocco; Emanuela Mancini; Rosanna Mancari; Cristina Vincenzoni; Giuseppe Cutillo; Enrico Vizza
Journal:  J Obstet Gynaecol Res       Date:  2021-12-28       Impact factor: 1.697

4.  Nursing of Vulvar Cancer Radical Operation Combined with Laparoscopic Inguinal Lymph Node Dissection.

Authors:  Simei Huang; Feifei Qiu
Journal:  Emerg Med Int       Date:  2022-09-05       Impact factor: 1.621

Review 5.  Feasibility and Safety of Video Endoscopic Inguinal Lymphadenectomy in Vulvar Cancer: A Systematic Review.

Authors:  Chai-E Liu; Yan Lu; De-Sheng Yao
Journal:  PLoS One       Date:  2015-10-23       Impact factor: 3.240

6.  Clinical application of sartorius tendon transposition during radical vulvectomy: a case control study of 58 cases at a single institution.

Authors:  Lei Li; Xinxin Kou; Xiaojie Feng; Fenghua Liu; Hongtu Chao; Liying Wang
Journal:  J Gynecol Oncol       Date:  2015-09-23       Impact factor: 4.401

7.  Treatment Outcomes of Patients with Squamous Cell Carcinoma of the Vulva: The Largest Series from a Tertiary Care Hospital.

Authors:  Panida Meelapkij; Prapaporn Suprasert; Orthai Baisai
Journal:  Obstet Gynecol Int       Date:  2018-09-03

8.  Comparison of the two routes of video endoscopic inguinal lymphadenectomy in vulvar cancer: a systematic review and a single-center experience.

Authors:  Lixia Luan; Rui Chen; Yang Yang; Fangfang Xue; Wenying Wang
Journal:  Transl Cancer Res       Date:  2021-02       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.